Salovum® reduces mortality in isolated severe traumatic brain injury: a randomized phase II trial.
David Cederberg, Bradley M Harrington, Iain Walker et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, double-blind, placebo-controlled phase II randomized trial tested Salovum® in adults with isolated severe traumatic brain injury receiving intracranial pressure monitoring and neurointensive care at a tertiary centre in Cape Town, South Africa. Among 100 participants, 30-day mortality was 20% with Salovum® and 39% with placebo (relative risk ratio 0.52; confidence interval: 0.271-0.997; P-value 0.040). Therapy intensity level and intracranial pressure were similar between groups, and no significant adverse events were noted. The authors conclude that further multicentre randomized trials are warranted.
Key findings
- Thirty-day mortality was 20% with Salovum® versus 39% with placebo (relative risk ratio 0.52; confidence interval: 0.271-0.997; P-value 0.040).
- Therapy intensity level and intracranial pressure were similar in the treatment and control groups.
- No significant adverse events were noted.
Why it matters
Severe traumatic brain injury carries substantial mortality, and the trial reports a lower 30-day mortality rate with Salovum® in a neurointensive-care population in South Africa. The result provides clinical evidence to inform further evaluation of this intervention, while the phase II design and single-centre setting mean it should be interpreted as preliminary rather than definitive.
What to keep in mind
This was a phase II trial conducted at one tertiary trauma centre, with 100 participants; the authors call for further multicentre randomized trials.